BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The Life Raft Group - ECPv6.17.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://liferaftgroup.org
X-WR-CALDESC:Events for The Life Raft Group
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200305T120000
DTEND;TZID=America/New_York:20200305T120000
DTSTAMP:20200228T201452Z
CREATED:20200228T201100Z
LAST-MODIFIED:20200228T201452Z
UID:10000055-1583409600-1583409600@liferaftgroup.org
SUMMARY:Webinar - New Treatment Options for Rare Diseases in the Soft Tissue - Day 1
DESCRIPTION:In honor of Rare Disease in the Soft Tissue Day\, OncLive is hosting webinars on March 5 and March 6 at 12pm EST about soft tissue sarcoma. GIST is a soft tissue sarcoma. \nDr. Jonathan Trent \nJonathan Trent\, MD\, PhD\, is a Professor of Medicine\, Associate Director of Clinical Research\, Director of the Sarcoma Program at Sylvester Comprehensive Cancer Center\, University of Miami\, Miller School of Medicine. \nDr. Trent is a recognized GIST expert. \nThe webinar will focus on: \n\nOverview of diagnosis and molecular testing\nCurrent treatment algorithms for soft tissue sarcoma\nNew therapeutic option for PDGFRA+ GIST\nFuture directions in management\n\nTo register for the March 5 webinar: \n\nRegister
URL:https://liferaftgroup.org/event/webinar-new-treatment-options-for-rare-diseases-in-the-soft-tissue/
LOCATION:NJ
CATEGORIES:Education,Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200306T120000
DTEND;TZID=America/New_York:20200306T120000
DTSTAMP:20200228T202614Z
CREATED:20200228T202106Z
LAST-MODIFIED:20200228T202614Z
UID:10000056-1583496000-1583496000@liferaftgroup.org
SUMMARY:Webinar - New Treatment Options for Rare Diseases in the Soft Tissue - Day 2
DESCRIPTION:In honor of Rare Disease in the Soft Tissue Day\, OncLive is hosting webinars on March 5 and March 6 at 12pm EST about soft tissue sarcoma. GIST is a soft tissue sarcoma. \nDr. Neeta Somaiah \nDr. Neeta Somaiah will present on March 6. She is an Associate Professor and the Director of Clinical Sarcoma Research\, Department of Sarcoma Medical Oncology\, UT MD Anderson Cancer Center. \nThe webinar will focus on: \n\nOverview of diagnosis and molecular testing\nCurrent treatment algorithms for soft tissue sarcoma\nNew therapeutic option for PDGFRA+ GIST\nFuture directions in management\n\nTo register for the March 6 webinar: \n\nRegister
URL:https://liferaftgroup.org/event/webinar-new-treatment-options-for-rare-diseases-in-the-soft-tissue-day-2/
LOCATION:NJ
CATEGORIES:Education,Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200323T120000
DTEND;TZID=America/New_York:20200323T130000
DTSTAMP:20200414T152639Z
CREATED:20200311T125440Z
LAST-MODIFIED:20200414T152639Z
UID:10000057-1584964800-1584968400@liferaftgroup.org
SUMMARY:LRG Webcast Series: New Treatment Options for Advanced GIST & Concerns about the Coronavirus
DESCRIPTION:Avapritinib is a medication used for the treatment of tumors due to one specific rare mutation: It is specifically intended for adults with unresectable or metastatic gastrointestinal stromal tumor that harbor a platelet-derived growth factor receptor alpha exon 18 mutation. \nRipretinib is an investigational broad-spectrum KIT and PDGFRα inhibitor in development for the treatment of patients with advanced gastrointestinal stromal tumors (GIST). \nDuring this webcast presentation\, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment. He will also address key questions for GIST patients concerning the coronavirus. \nListen to the recapAbout the Presenter:\n \nMichael Heinrich\, M.D.\nProfessor of Medicine and Cell/Developmental Biology\nOHSU School of Medicine \nDr. Heinrich earned his medical degree from Johns Hopkins School of Medicine in Baltimore and completed both his residency training and fellowship in hematology/medical oncology at OHSU. \nDr. Heinrich’s research\, like much of the work at the Knight Cancer Institute\, revolves around a basic\, yet complex premise. You have to understand what is broken in order to fix it. That’s why Dr. Heinrich is intently focused on identifying the molecular targets that cause cancer\, which is essential to the development of better and less toxic therapies. He is recognized internationally for groundbreaking research discoveries that have improved care for patients with gastrointestinal stromal tumors\, and his research has implications for many types of cancer. \n\nDisclaimer:\nWe cannot provide individual medical advice during this webcast. Information provided in this webcast is not intended as a substitute for your physician’s guidance and care.
URL:https://liferaftgroup.org/event/lrg-webcast-series-new-treatment-options-for-advanced-gist/
LOCATION:NJ
ATTACH;FMTTYPE=image/png:https://liferaftgroup.org/wp-content/uploads/2020/03/heinrich-event-v2.png
ORGANIZER;CN="Sara Rothschild":MAILTO:srothschild@liferaftgroup.org
END:VEVENT
END:VCALENDAR